Payment overview · 2025
General Payments
$321.17
16 reported records · 8 companies
Healthcare provider profile · identity verified
Cameron John Kurowski, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CANDLER, NC · NPI 1174584437
Verified facts
What the public records show
CMS Open Payments records show Cameron John Kurowski, MD received $321.17 in general payments during 2025 across 16 reported records.
PFIZER INC. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.89 | 25.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.46 | 18.5% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $57.42 | 17.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.57 | 14.5% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $22.56 | 7.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.79 | 6.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.46 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.02 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $321.17 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $65.32 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $59.46 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $57.42 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $46.57 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.22 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 103 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
19 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 290 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 274 | 73 |
| Losartan Potassium | Losartan Potassium | 261 | 67 |
| Gabapentin | Gabapentin | 235 | 47 |
| Atorvastatin Calcium | Atorvastatin Calcium | 230 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 218 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 217 | 50 |
| Omeprazole | Omeprazole | 188 | 43 |
| Tramadol Hcl | Tramadol Hcl | 181 | 36 |
| Metformin Hcl Er | Metformin Hcl | 175 | 42 |
| Trazodone Hcl | Trazodone Hcl | 162 | 39 |
| Lisinopril | Lisinopril | 149 | 43 |
| Oxycodone Hcl | Oxycodone Hcl | 142 | 17 |
| Alprazolam | Alprazolam | 131 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 22 |
| Clonazepam | Clonazepam | 112 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 31 |
| Buspirone Hcl | Buspirone Hcl | 109 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 25 |
| Eliquis | Apixaban | 103 | 16 |
| Furosemide | Furosemide | 101 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 27 |
| Carvedilol | Carvedilol | 91 | 19 |
| Famotidine | Famotidine | 90 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | 12 |
| Ozempic | Semaglutide | 79 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 19 |
| Montelukast Sodium | Montelukast Sodium | 65 | 12 |
| Lorazepam | Lorazepam | 59 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | suppressed |
| Allopurinol | Allopurinol | 55 | 13 |
| Meloxicam | Meloxicam | 55 | 17 |
| Memantine Hcl | Memantine Hcl | 55 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | suppressed |
| Pregabalin | Pregabalin | 54 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 53 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 53 | 11 |
| Baclofen | Baclofen | 50 | 13 |
| Belsomra | Suvorexant | 49 | suppressed |
| Bupropion Xl | Bupropion Hcl | 48 | 12 |
| Metformin Hcl | Metformin Hcl | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | suppressed |
| Atenolol | Atenolol | 41 | 12 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 16 |
| Methocarbamol | Methocarbamol | 39 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Simvastatin | Simvastatin | 36 | 12 |
| Spironolactone | Spironolactone | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 11 |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Prednisone | Prednisone | 25 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Emgality Pen | Galcanezumab-Gnlm | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 17 | 17 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Abilify Maintena | Aripiprazole | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $321.17 · 16 records | PFIZER INC. | ABRYSVO, COMIRNATY, ELIQUIS, EVENITY, INTELLIS ADAPTIVESTIM, Korlym, NURTEC ODT, PREVNAR 20, PROLIA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tymlos, VRAYLAR, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error